Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02531360 · ClinicalTrials.gov registry record · Early Phase 1
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
A Early Phase 1 study, sponsored by Molecular NeuroImaging.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT02531360 is a Early Phase 1 study that has completed, run by Molecular NeuroImaging. The registered enrollment target is 7 participants.
The verdict
NCT02531360, a Early Phase 1 study, has completed, sponsored by Molecular NeuroImaging.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The overall goal of this imaging trial is to characterize \[18F\]MNI-815, a PET radioligand for imaging Tau.
Interventions
- DRUG [18F]MNI-815 (MNI-815)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02531360
The ClinicalTrials.gov registry entry for NCT02531360 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Molecular NeuroImaging, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]MNI-815 (MNI-815) is the first listed.
NCT02531360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02531360 about?
NCT02531360 is a clinical study titled "Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies". The overall goal of this imaging trial is to characterize \[18F\]MNI-815, a PET radioligand for imaging Tau.
What is the current status of trial NCT02531360?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2015-05. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02531360?
The interventions under investigation include: [18F]MNI-815 (MNI-815) (DRUG).
Who is sponsoring clinical trial NCT02531360?
This trial is sponsored by Molecular NeuroImaging, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.